Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
Flörsch B, Taugner J, Käsmann L, Kenndoff S, Guggenberger J, Tufman A, Reinmuth N, Duell T, Belka C, Eze C, Manapov F. Flörsch B, et al. Among authors: kenndoff s. J Cancer Res Clin Oncol. 2023 Jul;149(7):3267-3276. doi: 10.1007/s00432-022-04174-z. Epub 2022 Aug 2. J Cancer Res Clin Oncol. 2023. PMID: 35915184 Free PMC article.
Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
Eze C, Guggenberger JE, Schmidt-Hegemann NS, Kenndoff S, Taugner J, Käsmann L, Schönecker S, Flörsch B, Li M, Belka C, Manapov F. Eze C, et al. Among authors: kenndoff s. Cancer. 2022 Jun 15;128(12):2358-2366. doi: 10.1002/cncr.34201. Epub 2022 Apr 13. Cancer. 2022. PMID: 35417563 Free article.
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study.
Käsmann L, Taugner J, Eze C, Nieto A, Pelikan C, Flörsch B, Kenndoff S, Hofer TP, Nössner E, Schulz C, Unterrainer M, Tufman A, Klauschen F, Jung A, Neumann J, Kumbrink J, Reinmuth N, Bartenstein P, Belka C, Manapov F. Käsmann L, et al. Among authors: kenndoff s. Transl Lung Cancer Res. 2022 Jul;11(7):1503-1509. doi: 10.21037/tlcr-21-1010. Transl Lung Cancer Res. 2022. PMID: 35958344 Free PMC article.
Prognostic significance of pretreatment PET parameters in inoperable, node-positive NSCLC patients with poor prognostic factors undergoing hypofractionated radiotherapy: a single-institution retrospective study.
Zinn AB, Kenndoff S, Holzgreve A, Käsmann L, Guggenberger JE, Hering S, Mansoorian S, Schmidt-Hegemann NS, Reinmuth N, Tufman A, Dinkel J, Manapov F, Belka C, Eze C. Zinn AB, et al. Among authors: kenndoff s. EJNMMI Rep. 2024 Oct 8;8(1):32. doi: 10.1186/s41824-024-00220-w. EJNMMI Rep. 2024. PMID: 39375264 Free PMC article.
 Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
Käsmann L, Eze C, Taugner J, Nieto A, Hofstetter K, Kröninger S, Guggenberger J, Kenndoff S, Flörsch B, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Käsmann L, et al. Among authors: kenndoff s. J Cancer Res Clin Oncol. 2023 Aug;149(10):7393-7403. doi: 10.1007/s00432-023-04654-w. Epub 2023 Mar 20. J Cancer Res Clin Oncol. 2023. PMID: 36939927 Free PMC article.
Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports.
Manapov F, Nieto A, Käsmann L, Taugner J, Kenndoff S, Flörsch B, Guggenberger J, Hofstetter K, Kröninger S, Lehmann J, Kravutske H, Pelikan C, Belka C, Eze C. Manapov F, et al. Among authors: kenndoff s. Expert Opin Investig Drugs. 2023 Mar;32(3):187-200. doi: 10.1080/13543784.2023.2179479. Epub 2023 Feb 22. Expert Opin Investig Drugs. 2023. PMID: 36780358